Additional file 1: of PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- Larissa Carnevalli (179142)
- Charles Sinclair (6158843)
- Molly Taylor (6158846)
- Pablo Gutierrez (6158849)
- Sophie Langdon (6158852)
- Anna Coenen-Stass (1571842)
- Lorraine Mooney (372137)
- Adina Hughes (6158855)
- Laura Jarvis (6158858)
- Anna Staniszewska (5892953)
- Claire Crafter (1981513)
- Ben Sidders (35030)
- Elizabeth Hardaker (6158861)
- Kevin Hudson (1629772)
- Simon Barry (255454)
Publication date
December 2018
DOIAbstract
Figure S1. Inhibition of PI3Kα/δ improves overall survival in CT-26 tumor and is active in low and high immunogenic immunocompetent models MC-38 and 4 T1. (A) Kaplan-Meyer curve shows survival fractions in CT-26 tumor bearing mice treated at indicated doses with AZD8835 at intermittent or continuous schedule (dashed and full blue line, respectively) and intermittent and continuous treatment with PI-3065 (dashed and full green line, respectively). Data are representative of ≥2 independent experiments. (PDF 60 kb
Add to ORKG